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Objectives The aim of this study was to determine the association of fetuin-A with subclinical cardiovascular disease (CVD)
in community-living individuals.
Background Fetuin-A is a hepatic secretory protein that inhibits arterial calcium deposition in vitro. Lower fetuin-A levels are
associated with arterial calcification and death in end-stage renal disease populations. The association of
fetuin-A with subclinical CVD in the general population is unknown.
Methods Among 1,375 community-living individuals without prevalent clinical CVD, we measured plasma fetuin-A concen-
trations. Peripheral arterial disease (PAD) was defined by ankle brachial index 0.90, coronary artery calcifica-
tion (CAC) was measured by computed tomography, and common and internal intima-media thickness (cIMT)
were measured by carotid ultrasound. PAD was measured concurrent with fetuin-A, and CAC and cIMT were
measured 4.6 years (mean) later.
Results Mean age was 70  11 years, and 64% were women. Fetuin-A levels were inversely associated with CAC sever-
ity. When evaluated as CAC categories (0, 1 to 100, 101 to 300, 300) with ordinal logistic regression, each SD
higher fetuin-A was associated with 31% lower odds of CAC severity (proportional odds ratio: 0.69; 95% confi-
dence interval: 0.46 to 0.92; p  0.008) in models adjusted for demographic data, lifestyle factors, traditional
CVD risk factors, and kidney function. In contrast, no association of fetuin-A was observed with PAD or high com-
mon or internal cIMT in adjusted models.
Conclusions Lower fetuin-A levels are independently associated with greater CAC severity but not PAD or cIMT. If confirmed,
fetuin-A might mark calcium deposition within the vasculature but not atherosclerosis per se. (J Am Coll
Cardiol 2011;58:2372–9) © 2011 by the American College of Cardiology Foundation
Published by Elsevier Inc. doi:10.1016/j.jacc.2011.08.035Fetuin-A is a protein secreted from the liver that inhibits
arterial calcium deposition in vitro (1). In serum, it interacts
with calcium and phosphorus, increasing their solubility and
inhibiting calcium crystal growth and precipitation, remi-
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accepted August 18, 2011.niscent of mechanisms by which lipoproteins solubilize
lipids. Consistent with this function, fetuin-A knockout
mice develop greater soft tissue calcification compared with
wild-type control mice when challenged with diets enriched
in vitamin D or phosphorus (2,3). As fetuin-A inhibits
arterial calcification within the blood stream, it raises the
possibility that blood levels might provide a useful marker of
the burden of arterial calcification.
Studies in end-stage renal disease (ESRD) populations
have consistently shown that lower fetuin-A levels are
associated with cardiovascular disease (CVD) events and
all-cause mortality (4–7). Most (8–11) but not all (12,13)
studies in ESRD have also reported that low fetuin-A levels
are associated with coronary or abdominal aortic calcifica-
tion. However, the associations of fetuin-A with subclinical
CVD events in the general population are much less clear.
Prior studies in individuals with known or clinically sus-
pected CVD have shown that lower fetuin-A levels are
associated with coronary artery calcification (CAC) (14) and
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November 29, 2011:2372–9 Fetuin-A and Subclinical CVDcardiac valve calcification (15), and 1 prior study in patients
with type 2 diabetes reported that lower fetuin-A levels are
associated with peripheral arterial disease (PAD) (16).
However, 2 other small studies (n  90 and n  315,
respectively) observed associations in the opposite direction,
reporting that higher fetuin-A levels were associated with
greater carotid intima-media thickness (cIMT) (17,18).
Enrollment criteria required known atherosclerosis in one
(18) and obesity, insulin resistance, or family history of
diabetes in the other (17). Comparing these studies is
difficult, not only because of seemingly conflicting directions
of associations but also because they studied select popula-
tions with either prevalent CVD, diabetes, or diabetic risk
factors (14–16,19,20). These conditions are marked by high
CVD risk and extensive arterial calcification burden.
To our knowledge, no study has evaluated the association
of fetuin-A with subclinical CVD in a single community-
dwelling population not selected on the basis of prevalent
disease or risk factors for disease. Therefore we sought to
determine the association of fetuin-A with subclinical CVD
in community-dwelling individuals without known clinical
CVD. We hypothesized that lower fetuin-A levels would be
associated with each marker of subclinical CVD, indepen-
dent of traditional CVD risk factors or kidney function.
Methods
Study participants. The Rancho Bernardo Study is a
prospective study of older community-dwelling individuals
designed to investigate the epidemiology of chronic diseases
in older adults. Between 1972 and 1974, all community-
dwelling residents living in Rancho Bernardo—a commu-
nity in Southern California—and 30 to 79 years of age were
invited to participate in a study of heart disease risk factors,
and 82% (n  5,052) enrolled. Nearly all were Caucasian,
middle to upper-middle class, and relatively well-educated.
Since then, sequential study visits have been conducted
approximately every 4 years. The present analysis included
individuals who participated in the 1992 to 1996 study visit
(n  1,781). Of these, 39 had insufficient stored blood
specimens for fetuin-A measurement, 349 were excluded
due to known prevalent clinical CVD (history of myocardial
infarction [MI], coronary artery bypass graft, or stroke), and
18 had missing covariate data, resulting in a final analytic
sample of 1,375 individuals. All participants gave written
informed consent; the study protocol was approved by the
human research protection program at the University of
California San Diego.
Fetuin-A. Fetuin-A was measured in plasma collected at
the 1992 to 1996 study visit with a human enzyme-linked
immunosorbent assay kit (Epitope Diagnostics, San Diego,
California). Samples were stored at 70°C until assayed in
2010. The assay uses a 2-site “sandwich” technique with
polyclonal antibodies that bind different epitopes of human
fetuin-A. Plasma samples were measured twice in each
participant, and results were averaged. Intra-assay andinterassay coefficients of variation
were 2.4% to 4.7% and 9.5% to
9.9%, respectively.
Subclinical CVD. CORONARY AR-
ERY CALCIUM. At the follow-up
visit subsequent to when blood
samples for fetuin-A measure-
ments were obtained (1998 to
2002), participants were invited
to have chest electron beam com-
puted tomography scans for
CAC. To be invited, participants
must: 1) have been evaluated by
our research team between 1997
and 1999; 2) be age 55 to 80
years; 3) be post-menopausal
(more than 1 year without men-
ses) if female; and 4) be free of
clinically manifest congenital
heart disease (no physician-
diagnosed angina, knockout, or
coronary artery revascularization). An Imatron C-150 ultra-
fast computed tomography scanner (Imatron, San Fran-
cisco, California) that produced contiguous thin-section
sections was used. Scans were electrocardiographically trig-
gered to the R-R interval, and images were obtained at
end-diastole during a single breath-hold; CAC was scored
according to the Agatston method (21). Of the 525 indi-
viduals who were invited, 2 were deceased, 15 were ineligi-
ble due to prevalent congenital heart disease, 57 declined the
invitation, 47 had moved from the local area or were not
seen due to scheduling problems, and 22 did not have
fetuin-A measurements available at the preceding visit,
yielding a study sample of 382 individuals for the CAC
analysis.
PAD. PAD was defined on the basis of ankle brachial
index (ABI) measurements made concurrent with collection
of samples for fetuin-A measurements (1992 to 1996 study
visit). With the participant in the supine position after 5
min of rest, a specially trained and certified nurse used a
mercury sphygmomanometer to measure the blood pressure
in each arm and leg. Systolic blood pressure (SBP) of the
brachial artery was used for the upper extremities, whereas
duplicate SBPs of the posterior tibial artery were used for
the 2 lower extremities. The ABI was calculated separately
for each leg by taking the higher SBP in each lower
extremity and dividing by the highest upper-extremity SBP.
The lowest of these 2 leg-specific ABIs was used to classify
the ABI score for each participant (22). PAD was defined as
an ABI 0.90. Among 1,375 individuals, 1,047 had ABI
measurements available; 2 were excluded for ABI values
1.30, because such individuals frequently have medial
arterial calcification and artifactually high ABI measure-
ments (23,24). This provided a final analytic sample of
Abbreviations
and Acronyms
ABI  ankle brachial index
BMI  body mass index
CAC  coronary artery
calcification
cIMT  carotid intima-
media thickness
CVD  cardiovascular
disease
eGFR  estimated
glomerular filtration rate
ESRD  end-stage renal
disease
MI  myocardial infarction
PAD  peripheral arterial
disease
SBP  systolic blood
pressure1,063 for PAD.
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follow-up visit subsequent to when blood samples for
fetuin-A measurements were obtained (1998 to 2002).
B-mode ultrasonography of the left and right common and
internal carotid arteries was performed by a specially trained
radiology technician. Briefly, 4 standardized images were
obtained on each participant: 1 at the lateral angle of the
common carotid artery, defined as the segment 1 cm
proximal to the dilation of the carotid bulb; and 3 for the
internal carotid artery at the site of maximal thickness in 3
distinct angles (anterior, posterior, and lateral). Ultrasound
measurements were recorded on super-VHS tapes and sent
to a central reading facility, where data were processed
blinded to all clinical data except for the cIMT ultrasound
images. The common cIMT was calculated as the mean of
the left and right measurements. Similarly, the internal
cIMT was determined as the mean of the 6 internal cIMT
measurements (25). All results are reported in millimeters.
Of the 1,375 individuals included in this study, 597 re-
turned and participated in the cIMT testing at the next
follow-up visit. All had available common cIMT measure-
ments, whereas 14 had internal cIMT measurements that
were deemed not interpretable, providing a sample size of
583 individuals for cIMT analysis.
Other measurements. Information on medical history,
edication use, physical exercise (3 times/week, yes or
o), alcohol consumption (3 drinks/week vs. less), and
urrent smoking (yes/no) was obtained with standardized
uestionnaires. Current medication use was validated by
xamination of pills and prescriptions brought to the clinic
or that purpose. Participants were asked to rate their overall
ealth on a 5-point scale (excellent, very good, good, fair, or
oor) and to report the number of hospital stays in the prior
ear.
Diabetes mellitus was defined as a fasting glucose 126
mg/dl, reported diagnosis of physician, or use of hypogly-
cemic medications. Systolic (SBP) and diastolic blood pres-
sure were measured twice in the seated position after 5 min
of rest, with the Hypertension Detection and Follow-up
Program protocol (26). Hypertension was defined as SBP
140 mm Hg, diastolic blood pressure90 mm Hg, or use
of antihypertensive medications. Height and weight were
measured with participants wearing light clothes and no
shoes, and body mass index (BMI) was calculated (weight
[kg]/height [m]2). Participants with BMI 30 kg/m2 were
lassified as obese. Blood samples were obtained by vena-
uncture between 7:30 AM and 11:00 AM after a requested
12-h fast; serum and plasma were separated and frozen at
70°C. Plasma total and high-density lipoprotein choles-
terol and triglycerides were measured in a Centers for
Disease Control-certified Lipid Research Clinic laboratory.
Low-density lipoprotein cholesterol was calculated with the
Friedewald equation (27). Serum creatinine was measured
with the rate Jaffe reaction and combined with age, sex, and
race in the Modification of Diet in Renal Disease equation
to obtain estimated glomerular filtration rate (eGFR) (28).Participants with eGFR 60 ml/min/1.73 m2 were classi-
fied as having moderate chronic kidney disease, according to
the National Kidney Foundation criteria (29).
Statistical analysis. We categorized participants into quar-
tiles of fetuin-A defined by the distribution within our study
population. Differences in demographic data and baseline
variables across the fetuin-A quartiles were evaluated with
analysis of variance or the chi-square test for categorical
variables. We visually inspected histograms of the distribu-
tion of each continuous variable in Table 1. When skewed
ariables were observed, we elected to use the Kruskal-
allis test in place of analysis of variance. In these in-
tances, we report the median and interquartile range within
ach quartile of fetuin-A. To maximize statistical power, we
sed multiple linear regression to evaluate the association of
etuin-A with each subclinical CVD measure on a contin-
ous scale. The CAC scores were right skewed, and 25%
ad CAC scores of 0. Thus, we added 1 to the CAC score
or each individual, natural log-transformed the resulting
ariable, and evaluated ln(CAC1) as the primary out-
ome. The resulting transformed variable more closely
pproximated a normal distribution. In companion analyses,
e evaluated categories of severity of CAC with cut-points
hat have been associated with increased risk of incident
VD in prior studies (CAC categories: 0, 1 to 100, 101 to
00, 300) (30) and used ordinal logistic regression models
n analysis. The proportional odds assumption was evaluated
ith the Score test, and no violations were observed. We
lso evaluated PAD (ABI 0.90 vs. 0.90) and common
and internal cIMT (75th percentile of each) on the
basis of dichotomous cut-points used in the Cardiovas-
cular Health Study and the Multi-Ethnic Study of
Atherosclerosis (31–33). Logistic regression was used to
evaluate these outcomes.
For each outcome, identical models were used to facilitate
comparisons. An initial model was adjusted for age and sex.
A second model additionally adjusted for lifestyle factors
(current smoking, alcohol use, regular physical exercise, and
oral estrogen use), and a final model additionally adjusted
for traditional CVD risk factors (diabetes, BMI, total
cholesterol, triglycerides) and eGFR. On the basis of our
prior work, we evaluated for effect modification in the
associations of fetuin-A with subclinical CVD by diabetes
by evaluating multiplicative interaction terms within the
final adjusted models (15,34). p values 0.05 were consid-
ered statistically significant for all analyses including inter-
action terms, and all analyses were performed with STATA
(version 11.0 SE, StataCorp LP, College Station, Texas).
Results
Among the 1,375-person study sample, the mean age was
70  11 years, and 64% (n  883) were women. Twelve
percent had diabetes, and 30% had moderate chronic kidney
disease. The median CAC score was 71 (interquartile range:
0 to 319), and the mean ABI, and common and internal
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m, respectively.
Table 1 shows the distribution of demographic data,
ifestyle factors, and CVD risk factors by fetuin-A quartiles.
ompared with the lowest quartile, individuals with higher
etuin-A levels were younger, more frequently female, and
onsumed less alcohol. Among women, use of oral estrogen
as associated with higher fetuin-A levels. Individuals with
igher fetuin-A levels and were also more likely to have
besity, diabetes, and an atherogenic lipid profile.
Table 2 shows the association of fetuin-A, both by quartiles
nd as a continuous predictor variable, with each marker of
ubclinical CVD evaluated as a continuous outcome measure.
etuin-A was inversely associated with CAC. This finding
emained consistent in models that adjusted for age and sex,
ife-style factors, traditional CVD risk factors, and kidney
unction. We observed no association of fetuin-A with ABI in
ge and sex or lifestyle adjusted models, but a statistically
ignificant direct association emerged in the final adjusted
odel. This association was of modest strength (each SD
igher fetuin-A associated with 0.01 higher ABI units). We
bserved no association of fetuin-A with common or internal
Baseline Characteristics of Community-Living Individuals by QuartilTable 1 Baseline Characteristics of Community-Living Individua
All
(n  1,375)
I
<0.45
(n  342)
Demographic data
Age (yrs) 70 11 73 12
Male 492 (36%) 138 (40%)
Lifestyle factors
Current smoking 107 (8%) 28 (8%)
Regular physical exercise 979 (71%) 243 (71%)
Alcohol 3 drinks/week 626 (46%) 178 (52%)
Health status
Oral estrogen use† 350 (25%) 53 (26%)
Fair or poor health status 83 (6%) 27 (8%)
Any hospital stays in past yr 106 (8%) 25 (8%)
Comorbidities 1 (0–2) 1 (0–2)
Medications 1 (1–1) 1 (1–1)
Comorbidities
Obese 161 (12%) 23 (7%)
Diabetes 170 (12%) 35 (10%)
Hypertension 674 (49%) 171 (50%)
Cardiovascular risk factors
Body mass index (kg/m2) 25 4 25 4
Systolic blood pressure (mm Hg) 135 22 134 21
Diastolic blood pressure (mm Hg) 76 9 75 10
Total cholesterol (mg/dl) 211 35 205 34
LDL cholesterol (mg/dl) 128 32 122 32
HDL cholesterol (mg/dl) 59 17 61 17
Triglycerides (mg/dl) 103 (73–146) 90 (67–121)
eGFR (ml/min/1.73 m2) 68 16 68 16
eGFR 60 ml/min/1.73 m2 413 (30%) 104 (30%)
Values are mean SD, n (%), or median (interquartile range). *p value across quartiles by analysis
eGFR  estimated glomerular filtration rate; HDL  high-density lipoprotein; LDL  low-densityIMT across the sequence of models.Table 3 shows the association of fetuin-A with each
outcome evaluated with clinically defined cut-points. In
this analysis, higher fetuin-A was also associated with less
severe CAC. Quartile analysis demonstrated a dose–
response relationship between fetuin-A and CAC cate-
gories (chi-square p  0.02) (Fig. 1). Among persons
ithout any CAC, 20% were in the lowest fetuin-A
uartile, whereas 28% were in the highest quartile.
onversely, among those with CAC scores 300, 36%
were in the lowest fetuin-A quartile, whereas only 13%
were in the highest. In contrast, there was no association
of fetuin-A with PAD or high internal cIMT defined as
categorical variables across the sequence of models (Table 3).
Each SD higher fetuin-A level was associated with 27%
greater odds of high common cIMT in a model adjusted for
lifestyle factors, but this association was attenuated and
rendered no longer statistically significant when adjusted for
traditional CVD risk factors and kidney function.
Last, we tested for effect modification in the association
of fetuin-A with each continuous measure of subclinical
CVD by diabetes. In all cases, results were similar (all
Plasma Fetuin-A: The Rancho Bernardo StudyQuartiles of Plasma Fetuin-A: The Rancho Bernardo Study
Fetuin-A Quartiles, Fetuin-A Range (g/l)
p Value*
II
0.45–0.51
(n  343)
III
0.52–0.58
(n  345)
IV
>0.59
(n  345)
70 11 69 11 68 11 0.001
132 (38%) 133 (39%) 89 (26%) 0.001
30 (9%) 21 (6%) 28 (8%) 0.58
261 (76%) 243 (70%) 232 (67%) 0.08
165 (48%) 155 (45%) 128 (37%) 0.001
75 (36%) 81 (38%) 141 (55%) 0.001
21 (6%) 18 (5%) 17 (5%) 0.34
27 (8%) 28 (8%) 26 (8%) 0.98
1 (0–2) 1 (0–2) 1 (0–2) 0.29
1 (1–1) 1 (1–1) 1 (1–1) 0.91
41 (12%) 50 (14%) 47 (14%) 0.01
37 (11%) 40 (12%) 58 (17%) 0.03
155 (45%) 171 (50%) 177 (51%) 0.41
26 4 26 4 26 4 0.001
134 22 135 24 135 21 0.94
76 9 77 9 77 9 0.03
209 36 212 35 217 36 0.001
128 32 130 32 130 31 0.05
59 16 58 17 59 18 0.18
96 (67–139) 110 (76–156) 123 (85–187) 0.001
68 14 69 18 68 14 0.48
105 (31%) 104 (30%) 1060 (29%) 0.97
nce, chi-square unless otherwise indicated. †Women only. p value obtained by Kruskal-Wallis test.
tein.es ofls byp values for interaction 0.24).
ular dis
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This study evaluated for the first time the associations of
plasma fetuin-A levels with subclinical CVD in a popula-
tion sample of community-dwelling men and women who
were free of clinical CVD. We observed that fetuin-A levels
were inversely associated with CAC severity, independent
of traditional CVD risk factors and kidney function. In
contrast, fetuin-A levels were not associated with PAD or
cIMT. In vitro studies, knockout studies in rodents, and
clinical studies in ESRD populations all suggest that
fetuin-A inhibits arterial calcification (2,3,5,35). Here, we
report that higher fetuin-A levels are also associated with
lower CAC prevalence in community-living individuals,
suggesting that fetuin-A might be serving a similar biolog-
ical function in this setting.
We had hypothesized that lower fetuin-A levels would be
associated with greater prevalence of PAD and higher
cIMT, and so the inverse association of fetuin-A with CAC
but not with PAD and cIMT was unexpected. However, if
confirmed, these findings might provide new insights into
vascular disease. Fetuin-A inhibits arterial calcium deposi-
tion, and any individual atherosclerotic lesion might be
characterized by more or less calcium content. Thus, low
fetuin-A might predispose to greater calcium deposition but
not necessarily to the burden or progression of atheroscle-
Association of Fetuin-A With Continuous Measures of Subclinical CTable 2 Association of Fetuin-A With Continuous Measures of
Fetuin-A Quartiles, Fe
I
<0.45
II
0.45–0.51
CAC (Ln[CAC  1])
n 86 97
Age- and sex-adjusted 1.00 (Ref) 0.33 (0.95 to 0.30), 0.31 0.32 (
Lifestyle-adjusted* 1.00 (Ref) 0.32 (0.95 to 0.31), 0.32 0.31 (
Fully adjusted† 1.00 (Ref) 0.40 (1.03 to 0.22), 0.21 0.44 (
Ankle brachial index
n 280 270
Age- and sex-adjusted 1.00 (Ref) 0.01 (0.01 to 0.04), 0.36 0.03 (0
Lifestyle-adjusted* 1.00 (Ref) 0.01 (0.01 to 0.03), 0.46 0.03 (0
Fully adjusted† 1.00 (Ref) 0.01 (0.01 to 0.04), 0.44 0.03 (0
Common cIMT
(ln[common cIMT])
n 131 150
Age- and sex-adjusted 1.00 (Ref) 0.02 (0.06 to 0.02), 0.30 0.01 (
Lifestyle-adjusted* 1.00 (Ref) 0.02 (0.06 to 0.02), 0.37 0.01 (
Fully adjusted† 1.00 (Ref) 0.03 (0.07 to 0.02), 0.25 0.01 (
Internal cIMT
(ln[internal cIMT])
n 125 149
Age- and sex-adjusted 1.00 (Ref) 0.004 (0.11 to 0.10), 0.94 0.04 (
Lifestyle-adjusted* 1.00 (Ref) 0.01 (0.10 to 0.11), 0.89 0.04 (
Fully adjusted† 1.00 (Ref) 0.004 (0.11 to 0.10), 0.95 0.02 (
Values are beta (95% confidence interval), p value. *Adjusted for age, sex, current smoking, alcohol
mass index, total cholesterol, triglycerides, and estimated glomerular filtration rate.
CAC  coronary artery calcification; cIMT  carotid intima media thickness; CVD  cardiovascrosis per se.Because low fetuin-A levels were associated with CAC
but not with PAD or common or internal IMT, an
alternative possibility is that fetuin-A is associated with
subclinical coronary atherosclerosis but not with atheroscle-
rosis in other vascular beds. Future studies that evaluate
whether low fetuin-A levels are more strongly associated
with incident MI as compared with stroke or PAD might
provide additional insights for this competing hypothesis.
Individuals with fetuin-A levels in the lowest quartile
were most likely to have severe CAC yet less likely to have
traditional CVD risk factors, including diabetes, hyperten-
sion, and hyperlipidemia. These findings raise the intriguing
hypothesis that measurement of fetuin-A might prove
useful as a risk marker for arterial calcification or CVD
events in individuals who would otherwise be considered
low risk by traditional CVD risk factors. However, the
biological significance of calcium deposition in atheroscle-
rotic lesions remains a matter of debate. Although it is
well-established that CAC score is a strong risk marker for
CVD events (30), this might be because CAC is marking
the total burden of atherosclerosis rather than causally
related to disease. Prior investigators have suggested that,
within individual lesions, calcium nodules might stimulate
plaque rupture (39), whereas others have suggested that
calcium has a stabilizing effect on individual plaques (40,41).
Thus, the association of fetuin-A with CVD events will be
he Rancho Bernardo Studylinical CVD: The Rancho Bernardo Study
Range (g/l)
Fetuin-A Continuous
per SD (0.11 g/l) Greater.58
IV
>0.59
5 104 382
to 0.31), 0.32 0.63 (1.25 to0.02), 0.04 0.24 (0.45 to0.02), 0.03
to 0.32), 0.33 0.58 (1.21 to 0.04), 0.07 0.21 (0.44 to 0.01), 0.06
to 0.20), 0.18 0.80 (1.44 to0.16), 0.01 0.31 (0.54 to0.08), 0.008
0 245 1,045
0.04), 0.02 0.01 (0.01 to 0.04), 0.34 0.01 (0.002 to 0.02), 0.15
o 0.05), 0.04 0.01 (0.01 to 0.04), 0.39 0.01 (0.003 to 0.02), 0.16
o 0.05), 0.03 0.02 (0.01 to 0.04), 0.16 0.01 (0.000 to 0.02), 0.04
8 168 597
to 0.04), 0.79 0.03 (0.01 to 0.07), 0.20 0.01 (0.002 to 0.03), 0.10
to 0.04), 0.82 0.03 (0.01 to 0.07), 0.20 0.01 (0.003 to 0.03), 0.11
to 0.03), 0.51 0.01 (0.03 to 0.06), 0.53 0.01 (0.01 to 0.02), 0.36
3 166 583
to 0.14), 0.47 0.06 (0.04 to 0.17), 0.23 0.02 (0.02 to 0.06), 0.26
to 0.15), 0.41 0.07 (0.03 to 0.18), 0.19 0.02 (0.01 to 0.06), 0.21
to 0.13), 0.71 0.02 (0.09 to 0.12), 0.75 0.001 (0.04 to 0.04), 0.95
gular physical exercise, and oral estrogen use. †Adjusted for lifestyle model () plus diabetes, body
ease.VD: TSubc
tuin-A
III
0.52–0
9
0.95
0.95
1.07
25
.01 to
.002 t
.002 t
14
0.05
0.05
0.06
14
0.07
0.06
0.09
use, rean important topic for future research. Moreover, although
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higher fetuin-A is also known to induce peripheral insulin
resistance in vitro (42–45); and in humans, higher fetuin-A
levels are associated with future risk of diabetes (46,47).
Diabetes is a well-established independent CVD risk factor.
Thus, there are plausible mechanisms through which either
low or high fetuin-A levels could be linked with incident
CVD, and evaluation of this association should be a high
priority moving forward. Few studies have evaluated this
association, and the existing studies are conflicting. The
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Figure 1 CAC Severity by Fetuin-A Quartiles:
The Rancho Bernardo Study
Distribution of coronary artery calcification (CAC) scores by fetuin-A quartiles
among 382 community-living individuals without clinically apparent cardiovascular
disease: The Rancho Bernardo Study.
Association of Fetuin-A With Categorical Definitions of SubclinicalTable 3 Association of Fetuin-A With Categorical Definitions of
Fetuin-A Q
I
<0.45
II
0.45–0.51
CAC severity (0, 1–100, 101–300, 300)
n with CAC 0/total (%) 69/86 76/97
Age- and sex-adjusted 1.00 (Ref) 0.74 (0.43 to 1.27), 0.2
Lifestyle-adjusted* 1.00 (Ref) 0.71 (0.41 to 1.24), 0.2
Fully adjusted† 1.00 (Ref) 0.65 (0.37 to 1.14), 0.1
PAD (ABI 0.90)
n with PAD/total (%) 40/280 36/270
Age- and sex-adjusted 1.00 (Ref) 0.99 (0.61 to 1.62), 0.9
Lifestyle-adjusted* 1.00 (Ref) 1.02 (0.62 to 1.67), 0.9
Fully adjusted† 1.00 (Ref) 1.05 (0.63 to 1.73), 0.8
Common cIMT (75th percentile vs. lower)
n with high common cIMT/total (%) 36/131 29/150
Age- and sex-adjusted 1.00 (Ref) 0.73 (0.40 to 1.32), 0.3
Lifestyle-adjusted* 1.00 (Ref) 0.72 (0.39 to 1.31), 0.2
Fully adjusted† 1.00 (Ref) 0.65 (0.35 to 1.20), 0.1
Internal cIMT (75th percentile vs. lower)
n with high internal cIMT/total (%) 27/125 33/149
Age- and sex-adjusted 1.00 (Ref) 1.06 (0.60 to 1.90), 0.8
Lifestyle-adjusted* 1.00 (Ref) 1.09 (0.60 to 1.95), 0.7
Fully adjusted† 1.00 (Ref) 1.05 (0.57 to 1.93), 0.8
Values are odds ratio (95% confidence interval), p value. *Adjusted for age, sex, current smoking, al
body mass index, total cholesterol, triglycerides, and estimated glomerular filtration rate.
PAD  peripheral arterial disease; other abbreviations as in Table 2.largest to date and the only study to evaluate community-
dwelling individuals observed that higher fetuin-A levels
were associated with incident MI and ischemic stroke (48).
However, another study evaluated individuals who pre-
sented in the emergency room with ST-segment elevation
MI and reported that lower levels were associated with
mortality (49). We previously evaluated a large sample of
individuals with known prevalent CVD at baseline who
experienced 182 recurrent CVD events and 220 deaths over
6 years. In this sample, we observed no statistically signifi-
cant association of fetuin-A with recurrent events or death
(50). Future large-scale studies are required to confirm the
nature, direction, and strength of the association of fetuin-A
with incident CVD events in the general community, and to
determine whether such associations might differ by diabe-
tes status.
Study strengths and limitations. Strengths of this study
include a well-characterized community-dwelling study
sample without prevalent CVD and availability of 3 mea-
sures of subclinical CVD. The study also has important
limitations. The CAC and IMT measurements were made
at a follow-up visit 4 years after measurement of fetuin-A,
and not all participants had these measurements available.
Because fetuin-A and each subclinical CVD measure were
made only once, this study cannot determine the temporal
directions of associations. Associations of fetuin-A with
PAD and IMT were null, and it is possible that a true
association with these outcomes was missed. We investi-
The Rancho Bernardo Studylinical CVD: The Rancho Bernardo Study
es, Fetuin-A Range (g/l)
Fetuin-A Continuous
per SD (0.11 g/l) Greater
III
0.52–0.58
IV
>0.59
66/95 75/104 286/382
72 (0.42 to 1.25), 0.24 0.58 (0.34 to 0.99), 0.04 0.81 (0.67 to 0.98), 0.03
71 (0.41 to 1.23), 0.22 0.56 (0.33 to 0.98), 0.04 0.81 (0.66 to 0.98), 0.03
61 (0.35 to 1.08), 0.09 0.45 (0.25 to 0.79), 0.006 0.72 (0.59 to 0.89), 0.002
25/250 28/245 129/1,045
73 (0.43 to 1.23), 0.24 0.88 (0.52 to 1.48), 0.62 0.93 (0.76 to 1.12), 0.43
72 (0.42 to 1.24), 0.24 0.87 (0.51 to 1.48), 0.60 0.92 (0.75 to 1.12), 0.40
73 (0.42 to 1.26), 0.26 0.78 (0.45 to 1.37), 0.39 0.88 (0.71 to 1.08), 0.22
32/148 52/168 149/597
77 (0.43 to 1.38), 0.38 1.79 (1.03 to 3.11), 0.04 1.27 (1.03 to 1.57), 0.02
76 (0.42 to 1.37), 0.35 1.76 (1.00 to 3.10), 0.05 1.27 (1.03 to 1.58), 0.03
65 (0.35 to 1.20), 0.17 1.50 (0.84 to 2.69), 0.17 1.20 (0.96 to 1.50), 0.11
38/143 47/166 145/583
32 (0.75 to 2.34), 0.34 1.66 (0.95 to 2.88), 0.07 1.19 (0.98 to 1.46), 0.08
34 (0.75 to 2.39), 0.32 1.66 (0.94 to 2.92), 0.08 1.20 (0.97 to 1.47), 0.09
26 (0.69 to 2.30), 0.45 1.35 (0.74 to 2.47), 0.32 1.10 (0.88 to 1.36), 0.40
se, regular physical exercise, and oral estrogen use. †Adjusted for lifestyle model () plus diabetes,CVD:Subc
uartil
7 0.
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0 0.
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cohol ugated each measure as a continuous variable to decrease the
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Fetuin-A and Subclinical CVD November 29, 2011:2372–9chance of type 2 errors. Nonetheless, results should be
interpreted within the context of the 95% confidence
intervals, which suggest that any missed association would
likely be modest, at best. Measurements of other novel
proteins that might inhibit arterial calcification were not
available concurrently with fetuin-A. Participants were pre-
dominantly older and Caucasian. Results might not gener-
alize to other settings.
Conclusions
In community-living individuals free of clinically apparent
CVD, low fetuin-A levels are independently associated with
CAC severity but not with PAD or cIMT. Future studies
are required to determine whether blood measurements of
fetuin-A are useful to assess systemic burden of arterial
calcification and to determine whether fetuin-A levels
might identify risk of incident CVD events in community-
dwelling individuals.
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